10-QPeriod: Q3 FY2024

BRISTOL MYERS SQUIBB CO Quarterly Report for Q3 Ended Sep 30, 2024

Filed October 31, 2024For Securities:BMYCELG-RIBMYMP

Summary

Bristol Myers Squibb (BMY) filed its 10-Q for the period ending September 29, 2024, presenting a snapshot of its financial performance and operational standing. While the provided excerpt doesn't contain detailed financial figures, it outlines the key sections investors should scrutinize, including the Consolidated Statements of Earnings and Comprehensive Income, Balance Sheets, and Cash Flows. Management's Discussion and Analysis (MD&A) will be crucial for understanding the drivers behind the company's performance, strategic decisions, and outlook. Investors should pay close attention to revenue trends, profitability, cash generation, and any significant updates on product pipelines, regulatory approvals, or litigation, as detailed in the subsequent sections of the filing.

Financial Highlights

56 data points
Beta

Revenue

$11.89B

75.1% Gross Margin

Net Income

$1.21B

10.2% Net Margin

EPS (Diluted)

$0.60

Total Assets

$93.67B

Cash & Equivalents

$7.89B

Free Cash Flow

$5.27B

Financial Statements
Beta
Revenue$11.89B
Cost of Revenue$2.96B
Gross Profit$8.94B
R&D Expenses$2.37B
SG&A Expenses$1.98B
Operating Expenses$10.22B
Net Income$1.21B
EPS (Basic)$0.60
EPS (Diluted)$0.60
Shares Outstanding (Basic)2.03B
Shares Outstanding (Diluted)2.03B

Key Highlights

  • 1The filing covers the quarterly period ending September 29, 2024, providing investors with up-to-date financial information.
  • 2Key financial statements, including the Consolidated Statements of Earnings and Comprehensive Income, Balance Sheets, and Cash Flows, are included for review.
  • 3Management's Discussion and Analysis (MD&A) is a critical section for understanding the company's operational performance and financial condition.
  • 4The report includes sections on Legal Proceedings and Risk Factors, which are essential for assessing potential challenges and uncertainties facing the company.
  • 5Information regarding Unregistered Sales of Equity Securities and Use of Proceeds is also presented.
  • 6The filing details Controls and Procedures, important for evaluating the reliability of financial reporting.
  • 7A summary of abbreviated terms is provided, aiding in the comprehension of the filing.

Frequently Asked Questions

This 10-Q filing provides Bristol Myers Squibb's quarterly financial statements and an overview of its financial condition and results of operations for the period ending September 29, 2024. It's a key document for investors to assess the company's performance and understand its business.

Investors should prioritize the 'Consolidated Statements of Earnings and Comprehensive Income', 'Consolidated Balance Sheets', and 'Consolidated Statements of Cash Flows' for detailed financial performance data. The 'Management’s Discussion and Analysis of Financial Condition and Results of Operations' is also vital for understanding the context and drivers behind these numbers.

Yes, the filing includes specific sections for 'Legal Proceedings' and 'Risk Factors'. Investors should review these to understand any ongoing legal challenges or potential risks that could impact the company's financial health and future operations.

The 'Management’s Discussion and Analysis of Financial Condition and Results of Operations' section is the primary location to find insights into the company's strategic decisions, operational performance, and its outlook for the future. Specific details will be elaborated within this section of the full filing.